Subscribe
shutterstock_716579470_nespix
nespix / Shutterstock.com
17 April 2019Americas

Catalent to buy $1.2bn gene therapy company

Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Thermo Fisher expands into gene therapy in $1.7bn deal
26 March 2019   Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.
Americas
Roche to make $4.3bn gene therapy acquisition
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Thermo Fisher expands into gene therapy in $1.7bn deal
26 March 2019   Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.
Americas
Roche to make $4.3bn gene therapy acquisition
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More on this story

Americas
Thermo Fisher expands into gene therapy in $1.7bn deal
26 March 2019   Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.
Americas
Roche to make $4.3bn gene therapy acquisition
25 February 2019   Switzerland-based Roche will buy gene therapy company Spark Therapeutics in a $4.3 billion deal.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent